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Edited by Varda RotterAbstract A small fraction of the total cellular amount of nucle-
ar transcription factor p53 seems to be located at and within
mitochondria. Transcription factors of the steroid receptor
superfamily that, like p53, lack a classical mitochondrial leader
sequence are nonetheless imported into mitochondria where they
regulate mtDNA transcription through binding to speciﬁc recog-
nition sequences. Here, we examined seven candidate sequences
from the human mitochondrial genome with similarity to the con-
sensus p53 binding motif. Two imperfect half-sites at coordinate
1553 with homology to the nuclear IGF-BP3 box A binding
sequence are demonstrated to confer responsivity to p53 and
the p53 relatives p73a and b in the context of the cell
nucleus. Mitochondrial p53 may thus bind directly to mtDNA
and, perhaps, be involved in the regulation of mitochondrial
transcription/replication.
 2004 Published by Elsevier B.V. on behalf of the Federation of
European Biochemical Societies.
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Transactivation1. Introduction
p53 is a predominantly nuclear, homotetrameric transcrip-
tion factor that is activated by various stresses (reviewed in
[1]). Up until recently, it was thought that activated p53 acts
mainly via the transcriptional regulation of genes whose prod-
ucts exert primarily one of two functions: they either arrest the
cell cycle, with the p21Waf inhibitor of cyclin-dependent ki-
nases as a major player, or they contribute to forcing cells into
apoptosis, with the BH (Bcl-2 homology domain) 123 protein
Bax and the BH3-only proteins PUMA and Noxa as examples
[2–5]. It is now known that p53 protein itself can be present at
the mitochondria and trigger the mitochondria-mediated death
machinery [6–10]. Several studies have furthermore suggested
p53 to be present even within the mitochondrial matrix, the
location where up to 10 mitochondrial (mt) DNA genomes
are transcribed and replicated [6,11]. Since there are several
precedents for the regulation of the mt DNA by nuclear tran-
scription factors which, like p53, lack a classical mitochondrial
import signal, it was interesting to ask whether there might be
p53-recognition motifs within the human mitochondrial
genome.*Corresponding author. Fax: +49 6841 1623980.
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doi:10.1016/j.febslet.2004.10.099p53 binds speciﬁcally to sequences composed of two 10-
mers (half-sites) with the degenerate consensus 5 0-r r r-C(A/
T)(A/T)G-y y y-3 0 (r, purines; y, pyrimidines) and spaced
by 0–13 bp [12]. Numerous studies have indicated that con-
formity to consensus, the numbers of half-sites in close prox-
imity and perhaps the presence of non-linear, stem-loop or
bent DNA, all constitute important parameters of binding
(reviewed in [13]). Furthermore, novel sequences with low
conformity to the consensus but high attraction for p53 have
recently been identiﬁed [14], and the protein has been shown
to be able to directly associate with mitochondrial transcrip-
tion factor A (mtTFA or TFAM) [15]. Here, we identify a se-
quence within the human mitochondrial 16S rDNA region
that can function as a p53 binding motif in the context of
the cell nucleus.2. Materials and methods
2.1. Cell culture, plasmids and transfection
Saos-2 and H1299 cells were cultured in DMEM, supplemented with
10% FCS and grown in a humidiﬁed 7% CO2 atmosphere at 37 C.
HCT116 cells and the p53/ derivatives were cultured in McCoys
medium under identical conditions. The human mitochondrial DNA
fragments were PCR-ampliﬁed and inserted into the pGA50-7 lucifer-
ase expression vector upstream of a b-globin minimal promoter and
luc gene. The used primer sequences will be provided upon request.
p21Waf-luc contained the p53-responsive p21Waf promoter in front
of a luc gene and served as a positive control. p53-recognition sequence
1553 was mutated from 5 0agaCAAGtcg–taaCATGgta3 0 to 5 0agaT-
AAAtcg–taaTATTgta3 0 by PCR mutagenesis; the promoter sequence
deletions shown in Fig. 3 were made by PCR cloning. For transient
transfection, exponentially growing cells in 12-well dishes were incu-
bated for 32 h with 0.4 lg of total DNA, of which 0.1 lg was reporter
vector, 0.1 lg was the green ﬂuorescence protein expressing plasmid
pEGFP-C3 (Clontech, Palo Alto, USA) included to normalize for
transfection eﬃciency in ﬂow cytometry analyses, 0.1 lg was one of
the CMV-driven eﬀector plasmids producing wt p53, p53 mutant 22/
23, p53 mutant 273H, p73a or p73b, and ﬁnally 0.1 lg was the anti-
apoptotic plasmid pCMV-E1B19K that prevented apoptosis induction
by p53 expression. As transfection reagent, eﬀectene from Qiagen (Hil-
den, Germany) was employed according to the manufacturers recom-
mendation for 12-well dishes. Luciferase assays were carried out using
the ‘‘Luciferase Assay System’’ (Promega, Mannheim, Germany) as
speciﬁed by the manufacturer.2.2. Antibodies and immunoblot analysis
The p53 monoclonal antibody DO-1 was purchased from Calbio-
chem (San Diego, USA); the anti-HA-tag antibody recognizing HA-
tagged p73 was from Sigma–Aldrich (Taufkirchen, Germany). Cells
from 10 cm dishes were lysed in 150 ll of a lysis buﬀer heated to 85
C and containing 50 mM Tris–HCl (pH 6.8), 100 mM DTT, 2%
SDS and 20% glycerol. Samples containing 15 lg of total cellular pro-ation of European Biochemical Societies.
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membrane (Immobilon-P, Millipore, Bedford, USA). Signals were de-
tected upon overnight incubation of the membranes with antibodies
followed by a ﬁnal incubation with a peroxidase-conjugated secondary
anti-mouse antibody and Renaissance Enhanced Luminol Reagents
(NEN, Boston, USA), performed as speciﬁed by the supplier.
2.3. Southwestern blotting
0.3 lg of each DNA sample was mounted onto a nitrocellulose
membrane (Schleicher & Schuell, Germany) and crosslinked with 120
J/m2 of UVC light. Membranes were washed twice in PBS and blocked
with 5% skimmed milk in PBS for 3 h. Cellular extracts were generated
as described [16], diluted to a protein concentration of 1 mg/ml in gel-
shift buﬀer (12.5 mM Tris–HCl, pH 7.9; 3.1 mM MgCl2; 25 mM KCl,
0.5 mM DTT; 10% glycerol; 0.25 mM EDTA; 0.2 mM PMSF; 10 lg/
ml leupeptin; 1 lg/ml pepstatin; 10 lg/ml aprotinin and 1 mg/ml of
pGL2-Basic plasmid DNA (Promega) for blocking) and incubated
overnight at 4 C with the membrane, followed by 3 · 5 min washes
in PBS–Tween (0.05%). The membrane was next incubated for 1 h with
antibody DO-1, followed by 3 · 5 min washes in PBS–Tween. A ﬁnal
incubation with a peroxidase-conjugated secondary anti-mouse anti-
body and Renaissance Enhanced Luminol Reagents was performed
as speciﬁed by the supplier.3. Results
When the human 16569 bp mitochondrial genome (Acc#
NC 001807; and [17]) was inspected for putative p53-recogni-
tion sequences, a total of seven candidate sequences were de-
tected (Fig. 1): 1553, 1809, 2397 and 2903 positioned within
the 12S and 16S rDNA region downstream of the heavy strand
promoter, HSP; 4637 situated within NADH dehydrogenase
subunit 2 gene; 12230 positioned between NADH dehydroge-
nase subunit 4 and 5 genes; and ﬁnally 16190 lying within the
regulatory D-loop, downstream of the light strand promoter,Fig. 1. Human mitochondrial genome sequences with similarities to the conse
the ﬁrst recognition sequence nucleotides (derived from human mtDNA sequ
related p53 binding site of a previously identiﬁed nuclear p53-responsive gen
p53AIP1). n is the number of spacing nucleotides. The arrows indicate p53 m
site. 1553 consists of ﬁve degenerate half-sites, spaced by zero to three bases.
and pyrimidine (y) tract nucleotides, and the bases that deviate from consenLSP (the numbers denote the position of the ﬁrst recognition
sequence nucleotide). Previous studies have shown that a cer-
tain degree of discordance with the consensus is tolerated as
long as the core invariant bases of the half-sites are main-
tained, and the alignments in Fig. 1 document that there is
an appreciable degree of homology between the putative mito-
chondrial p53 binding sites and previously identiﬁed recogni-
tion sequences from well-established nuclear p53-responsive
genes. One half-site, the second of sequence 2397, perfectly
matches the consensus. Furthermore, the ﬁrst half-site of
1553, the second of 2903, and the second of 16190, display just
one deviation from consensus at relaxed positions. However,
previous observations have strongly indicated that even half-
sites with two or three deviations at relaxed position (with
intact core invariant bases) may be functional when this deﬁ-
ciency is compensated by the presence of additional (imperfect)
half-sites in proximity [18]. Notable in this respect is 1553
which may consist of ﬁve imperfect half-sites, spaced by zero
to three basepairs. It is unclear at present whether conditions
exist under which spacer sequences of more than (the allowed)
13 bp can be bridged, perhaps through the formation of sec-
ondary structures.
Next, the identiﬁed sequences plus approximately 80 bp up-
stream and downstream were inserted in a reporter plasmid
harboring a b-globin minimal promoter and a luciferase gene
to study the responsiveness of these sequences in transient
transfections, in the context of the cell nucleus. The generated
reporter plasmids, a plasmid carrying the promoter sequences
of the p53-responsive p21Waf gene as positive control, and the
empty vector as a further control, were then each co-transfec-
ted into the p53-negative human osteosarcoma cell line Saos-2
along with either a wt p53-expressing eﬀector plasmid or thensus p53 binding motif (CON). The numbers denote the coordinates of
ence NC 001807). Each putative motif is aligned with the most closely
e (BP3, IGF-BP3 box A; Bax, Bax box A; PERP, PERP 2; and AIP,
onomer binding sites; two of these oriented head-to-head form a half-
The invariant bases in capital letters are separated from the purine (r)
sus are boldface and marked with an asterisk.
Fig. 2. p53 responsiveness of mtDNA-luc-reporter constructs upon
transient transfection of Saos-2 and H1299 cells. (a) Exponentially
growing Saos-2 cultures were transfected for 32 h with 0.1 lg reporter
vector, 0.1 lg pEGFP-C3 to normalize for transfection eﬃciency in
ﬂow cytometry analyses, 0.1 lg pCMV-E1B19K to inhibit p53-
meditated apoptosis, and 0.1 lg of either pCMV-p53 eﬀector plasmid
or empty vector (mock). Total cell extracts were prepared to determine
luciferase activity (fold-over-background). Reporter plasmid p21Waf-
luc served as positive control for p53 responsiveness. Error bars denote
SD derived from at least three experiments. (b) Transient transfection
of p21Waf-luc or 1553-luc as detailed in (a), with exponentially
growing H1299 cultures as target. (c) Transfection of Saos-2 cultures
as in (a), but with pCMV-p73a or pCMV-p73b as eﬀector plasmids.
Expression of the eﬀector proteins has been veriﬁed by Western
blotting (not shown).
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p53-expression plasmid was replaced with similar plasmids
producing the p53 relatives p73a or p73b [19]. Immunoblot
analyses had revealed that all eﬀector genes, driven by the
CMV promoter, were expressed at comparable levels (data
not shown). When luciferase assays were performed at 32 h
after transfection, the p21Waf promoter produced a strong sig-
nal indicative of p53 responsiveness, as expected. Surprisingly,
the mitochondrial sequence 1553, but none of the other se-
quences, also responded to p53, albeit much weaker than the
p21Waf promoter (Fig. 2(a)), indicating that 1553 harbors a
binding site with moderate to low aﬃnity for p53. A compara-
ble transactivation was observed upon transfection of the
p53-deﬁcient human H1299 lung adenocarcinoma cells, docu-
menting independence of cell type (Fig. 2(b)). Furthermore,
1553 was approximately twofold inducible by the two p73
proteins, which were not only less eﬀective than wt p53 on
this sequence but also on the p21Waf promoter, as expected
(Fig. 2(c)).
Stimulation of genes by p53 requires intact transactivation
and core DNA binding domains. When Saos-2 cells were
transfected as before and the p53-expression plasmid was re-
placed by vectors producing either the p53 transactivation do-
main mutant Q22/S23 or the DNA binding-defective mutant
273H, no transactivation of the p21Waf or 1553 reporter plas-
mids was observed (Fig. 3(a)), indicating that DNA contact
(through the core DNA binding domain) and the interaction
of p53 with factors of the basal transcription machinery
(through the transactivation domain) are necessary for the
transactivation of 1553. To further investigate precisely which
sequences within the 288 bp fragment that was denoted 1553
(containing the mitochondrial DNA sequences from position
1485 to 1772) were mediating the p53 responsiveness, reporter
plasmids with mutated fragments were generated. As is sum-
marized in Fig. 3(b), p53 responsiveness was maintained as
long as the ﬁrst binding motif of 1553 (comprising the ﬁrst
two half-sites of 1553 with zero bp spacer in Fig. 1) was intact.
Mutation of the four invariant bases within the 20-mer abro-
gated the response to p53. A second putative binding motif,
comprising the two half-sites between positions 1588 and
1607 (half-sites 4 and 5 of 1553 in Fig. 1) was not functional.
As in Fig. 2(c), the p73 proteins were less active on the full-
length regulatory sequences when compared with p53; how-
ever, their activity was increased when the sequences between
1573 and 1772 were eliminated (Fig. 3b), pointing to the pos-
sibility that a negative regulatory element is present within this
fragment. We thus conclude that the ﬁrst binding motif within
the mitochondrial 1553 sequence (1553–1572) can confer p53
responsivity to a reporter plasmid when transfected into the
cell nucleus.
To further study whether p53 can associate with 1553, an in
vitro protein–DNA binding assay based on the Southwestern
blotting procedure [16] was employed. For this purpose, the
p21Waf plasmid as a positive control, the 1553-luc plasmid,
and the luciferase plasmid pGA50-7 lacking the p21Waf and
mitochondrial sequences were immobilized on nitrocellulose
membranes. These were then incubated with nuclear extracts
from human wt p53-proﬁcient HCT116 colon carcinoma cells
treated with the DNA-damaging (p53 activating) drug ADR
(0.34 lM; Sigma), or with extracts from similarly treated p53-
deﬁcient HCT116 derivatives, and were exposed to anti-p53
antibody. As documented in Fig. 4, the extracts containingp53 produced a signal with the p21Waf-luc plasmid but not
with the pGA50-7 vector, while extracts from p53-null cells
failed to generate any signal, indicating that p53 associates with
known target sequences but not with vector in this experimental
setup. 1553-luc was also recognized by p53, in accord with the
Fig. 3. Characterization of the p53 functional domains and the 1553 sequence motifs required for p53 responsiveness. (a) Transient transfection of
Saos-2 cultures as detailed in Fig. 2(a), with p21Waf-luc or 1553-luc as reporters, and either empty vector, pCMV-p53, pCMV-p53-22/23, or pCMV-
p53-273H as eﬀector plasmids. (b) Transfection of Saos-2 cells with p53, p73a or p73b eﬀector plasmids, together with one of the indicated reporter
plasmids. Box 1553–1572 denotes the ﬁrst half-site as detailed in Fig. 1, box 1588–1507 the fourth and ﬁfth half-sites (the third was omitted because
of mutation of the third invariant base). The box marked with an asterisk depicts half-site 1553–1572 with invariant bases mutated (see Section 2 for
detail).
Fig. 4. In vitro-binding of p53 to immobilized plasmids with or
without p53-recognition sequences. The upper panel shows a Western
blot of extracts from HCT116 cells and HCT116 p53/ cells either
mock-treated or treated with ADR (0.34 lM) for 12 h. The p53
antibody DO-1 was used at a dilution of 1:1000. The lower panel
shows the result of Southwestern blots of membranes carrying 0.3 lg
of p21Waf-luc, 1553-luc or luciferase plasmid pGA50-7 (vector). The
membranes were incubated with extracts from ADR-treated p53-
positive or negative cells (italic), and were stained with p53 antibody
DO-1 at 1:1000 and a peroxidase-conjugated mouse secondary
antibody at 1:3000.
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has suggested a small fraction of p53 to be located within the
mitochondrial matrix of apoptotic [6] and even unstressed cells[11], we have so far failed to detect p53-mitochondrial DNA
complexes in chromatin immunoprecipitation (ChIP) assays.4. Discussion
Transcription of the circular mitochondrial genome is initi-
ated in opposite directions from two promoters (the HSP
and LSP) situated in close proximity to an approximately 1
kb triple DNA structure, the displacement (D) loop. Tran-
scription is accomplished by a bacteriophage-homologous, nu-
clear gene-encoded mitochondrial RNA polymerase, and is
required for the initiation of replication through RNA prim-
ing. Mitochondrial DNA replication is independent of the cell
cycle. Transcription results in the formation of three polycis-
tronic RNAs (two from HSP and one from LSP) that are even-
tually cleaved to produce separate mature RNAs (for review,
see [20]).
Both HSP and LSP are regulated by mitochondrial tran-
scription factor A (mtTFA or TFAM) belonging to the high
mobility group (HMG)-box family, and by the transcription
factors TFBM1 and 2 that contact the core RNA polymerase
[21]. Remarkable recent ﬁndings furthermore document that
nuclear transcription factors of the steroid receptor superfam-
ily may be directly involved in the regulation of mitochondrial
transcription without harboring typical amino-terminal mito-
chondrial leader sequences. An N-terminally truncated form
of the nuclear triiodothyronine receptor c-ErbAa1 has been
shown to recognize, in dependence of T3 ligand, mtDNA D-
loop sequences with similarity to nuclear T3 response ele-
ments, and to stimulate mitochondrial protein synthesis
[22,23]. Truncated c-ErbAa1 protein, like p53, fails to bind
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mitochondrial import mechanism allows retention of the mul-
timeric structure of c-ErbAa1, or that multimers can re-form
in the matrix of the organelle. Later observations have indi-
cated that a truncated version of the retinoic acid X receptor
(RXR) a is also located in the mitochondrial matrix and able
to regulate mitochondrial transcription, either through hetero-
dimerization with variant c-ErbAa1 or as homodimers and in
dependence of ligand [24]. Not least, the estrogen receptors
ERa and b have been located within the mitochondria, and
estrogen response elements have been identiﬁed in the mtDNA
[25,26].
While the mitochondrial estrogen receptor levels may ac-
count for more than 10% of the total cellular ER levels [25],
p53 seems to associate with the organelle in appreciable quan-
tities only during apoptosis [6,8,9]. In unstressed cells, p53 lev-
els are usually very low and the p53 levels that are detectable at
the mitochondria are even proportionately lower [11]. Is p53
involved in the regulation of mitochondrial transcription/repli-
cation, and if so, how? A ﬁrst hint implicating p53 in mito-
chondrial function was provided by the ﬁnding that
p53-deﬁcient mouse embryos show a secondary reduction in
mitochondrial 16S RNA transcript levels during embryonal
switch from anaerobic to aerobic metabolism [27]. A recent
in vitro extension of that work, employing a mitochondria-tar-
geted dominant-negative p53 miniprotein, has correlated bona
ﬁde absence of functional mitochondrial p53 with inhibition of
16S rRNA expression in murine NIH3T3 cells [28].
The human mitochondrial sequence 1553 identiﬁed here to
be p53 responsive is located within the 16S rDNA locus, not
too far upstream of the LSP and downstream of the HSP reg-
ulatory sequences. However, the analogous coordinates in the
mouse mt genome (AJ512208; position 976 corresponds to hu-
man 1553) show a C–T replacement in the critical ﬁrst invari-
ant base position, rendering unlikely a direct connection
between the previous ﬁndings (in the p53-knockout mice and
murine NIH3T3 cells, respectively) and our ﬁndings in human
cells. Of further interest in this context, the human sequence
1553 examined here is known to be polymorphic (http://
www.mitomap.org). The polymorphisms comprise (i) a G–A
replacement at position 1598 within the purine tract of puta-
tive half-site 1588–1607 (see Figs. 1 and 3(b)), which is neutral,
and (ii) an A–G replacement at position 1603, which mutates
an invariant base of the same half-site. However, Fig. 3(b) doc-
uments that this latter polymorphic half-site does not contrib-
ute to the p53 responsivity of sequence 1553 in transfection
assays. The critical half-site 1553–1572, by contrast, is con-
served within the primate lineage. Further work is required
to clear up whether 1553 is actually targeted by p53 in vivo
in the mitochondrion.
Finally, it should be noted that for p53 to regulate mito-
chondrial transcription or replication there need not be direct
DNA contact. The mitochondrial transcription factor mtTFA
(TFAM) has recently been documented to interact directly
with p53 [15]. Interestingly, this interaction apparently requires
a domain within p53 0s C-terminus that is modiﬁed by acetyla-
tion, and we have recently presented data suggesting that mito-
chondrial p53, in contrast to nuclear p53, is not acetylated [11].
The further observation by Yoshida and colleagues that p53can enhance the binding of mtTFA to cisplatin-damaged
DNA 10- to 20-fold [15] might even point to a role of p53 in
some forms of mtDNA damage repair. Future studies will ad-
dress whether p53 – or perhaps the p53-relative p73 – can reg-
ulate mitochondrial DNA directly, via speciﬁc recognition
sequences such as sequence 1553 identiﬁed here, or through
interaction with mtTFA.Acknowledgments: We express our gratitude to Dr. Matthias Dobbel-
stein (Marburg, Germany) for providing p73 plasmids. This work was
supported by Grant RO 1201/10-1 from the German Research Foun-
dation (DFG) to KR.References
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